User profiles for B. A. Perkins

Bruce A. Perkins

Professor of Medicine, Endocrinology and Metabolism, University of Toronto
Verified email at sinaihealthsystem.ca
Cited by 24534

Meningococcal disease

NE Rosenstein, BA Perkins, DS Stephens… - New England journal …, 2001 - Mass Medical Soc
Reports of illness resembling meningococcal disease date back to the 16th century. The
description reported by Vieusseux in 1805 is generally thought to be the first definitive …

[HTML][HTML] Bacterial meningitis in the United States in 1995

…, AL Reingold, L Lefkowitz, BA Perkins - New England journal …, 1997 - Mass Medical Soc
Background Before the introduction of the conjugate vaccines, Haemophilus influenzae
type b was the major cause of bacterial meningitis in the United States, and meningitis was …

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

DZI Cherney, BA Perkins, N Soleymanlou, M Maione… - Circulation, 2014 - Am Heart Assoc
… Dr Cherney has received speaker honoraria from Boehringer Ingelheim, and Dr Perkins
received operational funding with Dr Cherney for this work. Drs Soleymanlou, Fagan, Woerle, …

Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States.

…, JL Gerberding, JM Hughes, BA Perkins… - Emerging infectious …, 2001 - ncbi.nlm.nih.gov
From October 4 to November 2, 2001, the first 10 confirmed cases of inhalational anthrax
caused by intentional release of Bacillus anthracis were identified in the United States. …

Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications

HJL Heerspink, BA Perkins, DH Fitchett, M Husain… - Circulation, 2016 - Am Heart Assoc
… Dr Perkins has received speaker honoraria from Medtronic Inc., Johnson and Johnson,
Roche, Glaxo Smith Kline Canada, Novo Nordisk and Sanofi; has received research grant …

[HTML][HTML] Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes

…, C Joyce, T Peoples, BA Perkins… - … England Journal of …, 2010 - Mass Medical Soc
Background Recently developed technologies for the treatment of type 1 diabetes mellitus
include a variety of pumps and pumps with glucose sensors. Methods In this 1-year, …

[HTML][HTML] Regression of microalbuminuria in type 1 diabetes

BA Perkins, LH Ficociello, KH Silva… - … England Journal of …, 2003 - Mass Medical Soc
Background In the present study, we aimed to determine the frequency of a significant reduction
in urinary albumin excretion and factors affecting such reduction in patients with type 1 …

Simple screening tests for peripheral neuropathy in the diabetes clinic

BA Perkins, D Olaleye, B Zinman, V Bril - Diabetes care, 2001 - Am Diabetes Assoc
OBJECTIVE— The utility of rapid and reliable sensory tests appropriate for the diagnosis of
neuropathy in the diabetes clinic, rather than as prognostic tools for the prediction of foot …

[HTML][HTML] Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings

…, K Yeskey, S Zaki, DA Ashford, BA Perkins… - Emerging infectious …, 2002 - ncbi.nlm.nih.gov
In October 2001, the first inhalational anthrax case in the United States since 1976 was
identified in a media company worker in Florida. A national investigation was initiated to identify …

Serological response to" Rochalimaea henselae" antigen in suspected cat-scratch disease

RL Regnery, JG Olson, BA Perkins, W Bibb - The Lancet, 1992 - Elsevier
There are no generally accepted diagnostic tests for cat-scratch disease (CSD), the cause
of which is unknown. During the development of an indirect fluorescence antibody (IFA) test …